March 20, 2025 · GlobeNewswire
Pathos AI Doses First Patient in Phase 1b/2a Trial of Pocenbrodib
The trial evaluates pocenbrodib, an investigational CBP/p300 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC).
Pathos AI announced that the first patient has been dosed in a multicenter, open-label, dose-finding study of pocenbrodib, given alone and in combination with abiraterone acetate, olaparib, or 177Lu-PSMA-617. Pocenbrodib is the first clinical-stage asset in Pathos's pipeline.
The study (P300-02-001, NCT06785636) is expected to enroll approximately 203 adults with mCRPC whose disease progressed after prior therapy. Its primary objectives are to assess safety, objective response rate, and PSA decline, and to define a preliminary recommended Phase 2 dose.
Read the full releaseSource: Pathos AI, via GlobeNewswire. Pocenbrodib is an investigational therapy and has not been approved by the FDA or any other regulatory authority.